Pregnancy and exogenous hormones in patients with cutaneous malignant melanoma

Current Opinion in Oncology

Volumn 11, Issue 2, 1999, Pages 129-131

  MacKie, Rona M ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ORAL CONTRACEPTIVE AGENT;

CANCER STAGING; DRUG SAFETY; FEMALE; HORMONAL THERAPY; HORMONE SUBSTITUTION; HUMAN; MELANOMA; ORAL DRUG ADMINISTRATION; PREGNANCY; PRIORITY JOURNAL; SHORT SURVEY;

CONTRACEPTIVES, ORAL; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; MELANOMA; NEOPLASMS, HORMONE-DEPENDENT; PREGNANCY; PREGNANCY COMPLICATIONS, NEOPLASTIC; SKIN NEOPLASMS;

EID: 0033033030     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-199903000-00009     Document Type: Short Survey

References (15)

1. MacKie RM, Hole D, Hunter JAA, Rankin R, Evans A, McLaren K, on behalf of the Scottish Melanoma Group: Cutaneous malignant melanoma in Scotland: incidence, survival, and mortality, 1979-94. Br Med J 1997, 315:1117-1121. A useful population-based review of all melanomas in a geographic area over a 15-year period.
2. MacKie RM, Bufalino R, Morabito, Sutherland C, Cascinelli N, for the World Health Organisation Melanoma Program: Lack of effect of pregnancy on outcome of melanoma. Lancet 1991, 337:653-655.
3. Wong JH, Stems EE, Kopald KH, Nizze JA, Morton DL: Prognostic significance of pregnancy in stage 1 melanoma. Arch Surg 1989, 124:1227-1231.
4. Slingluff CL, Reintgen DS, Vollmer RT, Seigler HF: Malignant melanoma arising during pregnancy: a study of 100 patients. Am Surg 1990, 211:552-559.
5. Travers RL, Sober AJ, Berwick M, Mihm MC Jr, Barnhills RL, Duncan IM: Increased thickness of pregnancy-associated melanoma. Br J Dermatol 1995, 132:876-883.
6. Driscoll MS, Grin-Jorgensen CM, Grant-Kels JM: Does pregnancy influence the prognosis of malignant melanoma? J Am Acad Dermatol 1993, 29:619-630.
7. Pennoyer JW, Grin CM, Driscoll MS, Dry SM, Walsh SJ, Gelineau JP, Grant-Kels JM: Changes in size of melanocytic nevi during pregnancy. J Am Acad Dermatol 1997, 36:378-382. Although it needs to be repeated on a larger scale, this is a useful study suggesting that some of the old wives' tales about nevi and pregnancy should be discounted.
8. Johnston SRD, Broadley K, Henson G, Fisher C, Henk M, Gore ME: A difficult case: management of metastatic melanoma during pregnancy. Br Med J 1998, 316:848-849. A very interesting account of the problem of managing metastatic melanoma during pregnancy.
9. Baergen RN, Johnson D, Moore T, Benirschke K: Maternal melanoma metastatic to the placenta. Arch Pathol Lab Med 1997, 121:508-511. A useful case report with an excellent review of the world literature on placenta metastases.
10. Gefeller O, Hassan K, Willie L: Cutaneous malignant melanoma in women and the role of oral contraceptives. Br J Dermatol 1998, 138:122-124. A large systematic review confirming the absence of effect on melanoma risk in women who use oral contraceptives.
11. Pfahlberg A: Systematic review of case control studies: oral contraceptives show no effect on melanoma risk. Public Health Rev 1997, 25:309-315. Another useful Cochrane-type review showing no effect on melanoma risk.
12. Hartmann BW, Huber JC: The mythology of hormone replacement therapy. Br J Obstet Gynaecol 1997, 104:163-168.
13. Lecavalier MA, From L, Gaid N: Absence of estrogen receptors in dysplastic nevi and malignant melanoma. J Am Acad Dermatol 1990, 23:242-246.
14. Flowers JL, Seigler HF, McCarty KS, Konrath J, McCarty KS Jr: Absence of estrogen receptor in human melanoma as evaluated by a monoclonal antiestrogen receptor antibody. Arch Dermatol 1987, 123:764-765.
15. Neifeld JP, Lippman ME: Steroid hormone receptors and melanoma. J Invest Dermatol 1980, 74:379-381.